ZA200201754B - New pyrimidine,2,4,6-trioe derivatives, processes for their production and pharmaceutical agents containing these compounds. - Google Patents

New pyrimidine,2,4,6-trioe derivatives, processes for their production and pharmaceutical agents containing these compounds. Download PDF

Info

Publication number
ZA200201754B
ZA200201754B ZA200201754A ZA200201754A ZA200201754B ZA 200201754 B ZA200201754 B ZA 200201754B ZA 200201754 A ZA200201754 A ZA 200201754A ZA 200201754 A ZA200201754 A ZA 200201754A ZA 200201754 B ZA200201754 B ZA 200201754B
Authority
ZA
South Africa
Prior art keywords
phenyl
phenoxy
piperazin
pyrimidin
trioxo
Prior art date
Application number
ZA200201754A
Other languages
English (en)
Inventor
Frank Grams
Herbert Leinert
Gerd Zimmermann
Hans-Willi Krell
Ernesto Menta
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200201754B publication Critical patent/ZA200201754B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200201754A 1999-10-01 2002-03-01 New pyrimidine,2,4,6-trioe derivatives, processes for their production and pharmaceutical agents containing these compounds. ZA200201754B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99119506 1999-10-01

Publications (1)

Publication Number Publication Date
ZA200201754B true ZA200201754B (en) 2003-06-02

Family

ID=8239103

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200201754A ZA200201754B (en) 1999-10-01 2002-03-01 New pyrimidine,2,4,6-trioe derivatives, processes for their production and pharmaceutical agents containing these compounds.

Country Status (28)

Country Link
US (1) US6498252B1 (fr)
EP (1) EP1226128B1 (fr)
JP (1) JP3848160B2 (fr)
KR (1) KR100459975B1 (fr)
CN (1) CN1157382C (fr)
AR (1) AR033651A1 (fr)
AT (1) ATE289595T1 (fr)
AU (1) AU768309B2 (fr)
BR (1) BR0014678A (fr)
CA (1) CA2385863C (fr)
CO (1) CO5210860A1 (fr)
CZ (1) CZ20021535A3 (fr)
DE (1) DE60018301T2 (fr)
ES (1) ES2235955T3 (fr)
HU (1) HUP0202832A3 (fr)
IL (1) IL148573A0 (fr)
MA (1) MA26823A1 (fr)
MX (1) MXPA02003192A (fr)
NO (1) NO20021380D0 (fr)
NZ (1) NZ517635A (fr)
PE (1) PE20010659A1 (fr)
PL (1) PL202680B1 (fr)
RU (1) RU2248971C2 (fr)
TR (1) TR200200858T2 (fr)
UY (1) UY26362A1 (fr)
WO (1) WO2001025217A1 (fr)
YU (1) YU22102A (fr)
ZA (1) ZA200201754B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716845B2 (en) * 2001-03-30 2004-04-06 Hoffmann-La Roche Inc. Barbituric acid derivatives
WO2003053940A1 (fr) 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Derives d'acide barbiturique utilises comme inhibiteurs de l'enzyme de conversion du tnf-$g(a) (tace) et/ou de metalloproteinases matricielles
WO2004084903A1 (fr) * 2003-03-27 2004-10-07 F. Hoffmann-La Roche Ag Utilisation d'une trioxopyrimidine pour le traitement et la prevention de l'angiogenese pathologique oculaire
WO2004084902A1 (fr) * 2003-03-28 2004-10-07 F. Hoffmann-La Roche Ag Utilisation d'une trioxopyrimidine dans le traitement de lesions chroniques
CN100558362C (zh) * 2004-04-01 2009-11-11 霍夫曼-拉罗奇有限公司 三氧嘧啶治疗和预防支气管炎症疾病的应用
KR100771411B1 (ko) 2004-04-01 2007-10-30 에프. 호프만-라 로슈 아게 피리미딘-2,4,6-트리온의 시클로덱스트린 포접 복합체
EP1632489A1 (fr) * 2004-08-24 2006-03-08 University of Liege Dérivés de 5-(1,1'-Biphényl)-4-yl-5-(4-(4-aminoacylphényl)-pipérazin)-1-yl-pyrimidine-2,4,6-trione comme inhibiteurs de zinc metalloendopeptidase, leur préparation et utilisation.
RU2449994C1 (ru) * 2011-03-10 2012-05-10 Светлана Алексеевна Мещерякова 6-(4-бензилпиперазино)-1,3-диметилурацила дигидрохлорид, проявляющий биологическую активность
RU2598607C1 (ru) * 2015-07-16 2016-09-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный университет" (Астраханский государственный университет) Способ получения 5-гетарилметиленпиримидин-2,4,6-трионов

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1246743B (de) * 1965-01-12 1967-08-10 Dresden Arzneimittel Verfahren zur Herstellung von 5-Phenyl-5-piperidinobarbitursaeuren
US4595700A (en) 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
GB8726714D0 (en) 1987-11-14 1987-12-16 Beecham Group Plc Compounds
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5239078A (en) 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
CA2073510A1 (fr) 1990-12-03 1992-06-04 Celltech Therapeutics Limited Derives peptidyles
CA2058797A1 (fr) 1991-02-01 1992-08-02 Michael John Broadhurst Derives d'aminoacide
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
DE69633947T2 (de) 1995-12-08 2005-12-01 Agouron Pharmaceuticals, Inc., San Diego Zwischenprodukte zur Herstellung von Metallproteinasehemmern
DE19548624A1 (de) 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers

Also Published As

Publication number Publication date
EP1226128A1 (fr) 2002-07-31
CN1374954A (zh) 2002-10-16
PL357385A1 (en) 2004-07-26
PL202680B1 (pl) 2009-07-31
NO20021380L (no) 2002-03-20
ES2235955T3 (es) 2005-07-16
JP3848160B2 (ja) 2006-11-22
NZ517635A (en) 2003-11-28
PE20010659A1 (es) 2001-06-20
RU2248971C2 (ru) 2005-03-27
US6498252B1 (en) 2002-12-24
KR100459975B1 (ko) 2004-12-03
BR0014678A (pt) 2002-07-23
IL148573A0 (en) 2002-09-12
YU22102A (sh) 2004-11-25
TR200200858T2 (tr) 2002-07-22
ATE289595T1 (de) 2005-03-15
CN1157382C (zh) 2004-07-14
KR20020039356A (ko) 2002-05-25
DE60018301D1 (de) 2005-03-31
CA2385863C (fr) 2009-04-14
DE60018301T2 (de) 2006-04-06
MA26823A1 (fr) 2004-12-20
UY26362A1 (es) 2001-04-30
AU7784900A (en) 2001-05-10
WO2001025217A1 (fr) 2001-04-12
CO5210860A1 (es) 2002-10-30
AR033651A1 (es) 2004-01-07
JP2003511376A (ja) 2003-03-25
AU768309B2 (en) 2003-12-04
HK1050198A1 (en) 2003-06-13
EP1226128B1 (fr) 2005-02-23
NO20021380D0 (no) 2002-03-20
CA2385863A1 (fr) 2001-04-12
MXPA02003192A (es) 2002-09-30
CZ20021535A3 (cs) 2002-11-13
HUP0202832A2 (hu) 2003-02-28
HUP0202832A3 (en) 2003-03-28

Similar Documents

Publication Publication Date Title
US6110924A (en) Barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds
MC2076A1 (fr) Composes ayant un effet sur le systeme nerveux central et utilisables comme substances actives de medicaments
HUP0202501A2 (hu) Pirimidin-2,4,6-trion metalloproteináz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
JP2002504916A (ja) 抗転移及び抗腫瘍活性を有するバルビツール酸誘導体
AU768309B2 (en) New pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds
AU2002302470B2 (en) Pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing them
AU2002302470A1 (en) Pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing them
EP0922702A1 (fr) Dérivés de l'azulène et compositions pharmaceutiques les contenant
US3896129A (en) (2-pyrimidinylthio) alkanoic acids, esters, amides and hydrazides
CA2240845C (fr) Nouveaux derives d'acide barbiturique, leurs procedes de production et substances pharmaceutiques contenant lesdits derives
HK1050198B (en) New pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds
EP1632489A1 (fr) Dérivés de 5-(1,1'-Biphényl)-4-yl-5-(4-(4-aminoacylphényl)-pipérazin)-1-yl-pyrimidine-2,4,6-trione comme inhibiteurs de zinc metalloendopeptidase, leur préparation et utilisation.